Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs, rapidly mobilizing these cells from the bone marrow into the peripheral blood. In preclinical ...
Celebrity endorsements drive propranolol trend among women seeking non-addictive anxiety relief, though FDA hasn't approved ...
According to the data presented at the American Society of Hematology Annual Meeting, 17 of 19 participants (89.5%) successfully collected the required number of CD34+ cells within two leukapheresis ...
Exicure (XCUR) announced results from its completed Phase 2 trial evaluating burixafor in combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic ...
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026BOSTON, Dec. 04, 2025 (GLOBE ...
The heart medication can ease physical symptoms of panic, making them popular for job interviews, public speaking events and ...